( September 23, 2024, 1:40 PM EDT) -- WASHINGTON, D.C. — The Federal Trade Commission on Sept. 20 filed an administrative complaint against three prescription drug benefit managers (PBMs) accusing them of creating “a perverse drug rebate system that prioritizes high rebates from drug manufacturers, leading to artificially inflated insulin list prices,” according to a press release from the commission....